Nordic pharmaceutical company Navamedic (Oslo: NAVA) announced on Wednesday that it has expanded its portfolio of antibiotics for hospital use, under an agreement with its partner InfoRLife SA, a subsidiary of ACS Dobfar S.p.A.
This agreement means that Navamedic has acquired the rights and marketing authorisations for Clindamycin ready-to-administer bags developed and manufactured by InfoRLife AS.
According to Navamedic, Clindamycin is an antibiotic used to treat severe infections, including staphylococcal bone and joint infections, chronic sinusitis and infections of the lower respiratory tract. This ready-to-use packaging provides benefits such as a reduction in medication errors, reduced risk of contamination, storage at ambient temperature and saving on nurse time, as well as a reduction of waste.
The company added that it already markets Clindamycin in traditional ampoules as part of the large portfolio of antibiotics acquired from ACS Dobfar in 2020.
Regeneron and Sanofi's Dupixent gains EU approval for uncontrolled COPD with eosinophilia
INOVIO names new chief commercial officer
Carisma Therapeutics names new directors
Biophytis reports positive Phase 2/3 results for COVID-19 treatment at WCID
Biophytis signs Latin American deal with Blanver for BIO101 (20-Hydroxyecdysone)
Natera unveils enhanced Prospera Heart test for transplant patients
Biophytis reports industrial scale production of DMD drug candidate BIO101
EMA grants orphan drug designation to Moleculin's Annamycin for AML
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
ProAxsis secures GBP1.8m investment
CareDx highlights cardiothoracic advancements at ISHLT meeting